<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease (BD) is prevalent in Central and East Asia and in the Eastern Mediterranean area where most studies have been performed </plain></SENT>
<SENT sid="1" pm="."><plain>Few studies have evaluated patients with BD in Brazil </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVES: The objective of the study was to describe clinical manifestations of BD and their therapy in a single center in Brazil </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Sixty patients who met the International Study Group Criteria for BD and were under follow-up at the <z:hpo ids='HP_0002633'>Vasculitis</z:hpo> Unit of the Universidade Federal de São Paulo were evaluated in a retrospective observational study </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Mean age at study was 40.0 (SD, 10.7) years, and the female-male ratio was 1.2:1.0 </plain></SENT>
<SENT sid="5" pm="."><plain>The frequency of disease manifestations was as follows: <z:hpo ids='HP_0000155'>oral ulcers</z:hpo>, 100%; <z:hpo ids='HP_0003249'>genital ulcers</z:hpo>, 93.3%; ocular manifestations, 63.3%; <z:hpo ids='HP_0001369'>arthritis</z:hpo>, 46.7%; cutaneous lesions, 71.7%; positive <z:e sem="disease" ids="C0878631" disease_type="Disease or Syndrome" abbrv="">pathergy</z:e> test, 22.7%; neurologic involvement, 28.3%; <z:mp ids='MP_0005048'>thrombosis</z:mp>, 13.3%; and gastrointestinal involvement, 3.3% </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001369'>Arthritis</z:hpo> and <z:hpo ids='HP_0010783'>erythema</z:hpo> nodosum were more prevalent among women, whereas papulopustular lesions were more common in men </plain></SENT>
<SENT sid="7" pm="."><plain>The frequency of each treatment modality was as follows: <z:chebi fb="0" ids="23359">colchicine</z:chebi>, 78.3%; thalidomide, 26.7%; <z:chebi fb="0" ids="23359">colchicine</z:chebi> and <z:chebi fb="93" ids="17334">penicillin</z:chebi>, 21.7%; dapsone, 8.3%; and pentoxyphyline, 8.3% </plain></SENT>
<SENT sid="8" pm="."><plain>These treatments were mainly used for mucocutaneous manifestations </plain></SENT>
<SENT sid="9" pm="."><plain>Immunosuppressive drugs were prescribed for 70% of the patients, including <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (35.0%), <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (28.3%), <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (21.7%), <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (18.3%), and <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> (6.7%) </plain></SENT>
<SENT sid="10" pm="."><plain>Infliximab was used in 5.0% of refractory patients </plain></SENT>
<SENT sid="11" pm="."><plain>No differences were observed between sexes related to severe manifestations of BD </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Although reported elsewhere, Brazilian men with BD did not have a worse prognosis </plain></SENT>
<SENT sid="13" pm="."><plain>Women had a higher frequency of <z:hpo ids='HP_0001369'>arthritis</z:hpo> manifestations </plain></SENT>
</text></document>